HPM Partners LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 967.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,435 shares of the medical instruments supplier’s stock after buying an additional 24,864 shares during the period. HPM Partners LLC’s holdings in Becton, Dickinson and were worth $1,661,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Becton, Dickinson and by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Becton, Dickinson and by 6.5% during the 1st quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after buying an additional 242,081 shares during the last quarter. Fundsmith LLP increased its holdings in shares of Becton, Dickinson and by 3.2% during the 1st quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock worth $421,291,000 after buying an additional 71,691 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Becton, Dickinson and by 8.4% during the 1st quarter. Geode Capital Management LLC now owns 1,941,743 shares of the medical instruments supplier’s stock worth $355,653,000 after buying an additional 151,238 shares during the last quarter. Institutional investors and hedge funds own 87.12% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 198.08 on Friday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm has a market capitalization of $45.08 billion, a P/E ratio of 57.36 and a beta of 1.05. The stock’s 50 day moving average price is $197.22 and its 200 day moving average price is $192.46.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.35 EPS. On average, analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were issued a $0.73 dividend. The ex-dividend date of this dividend was Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.47%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

Several analysts recently issued reports on BDX shares. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a report on Tuesday, September 12th. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a report on Monday, July 17th. Finally, Cowen and Company reiterated a “buy” rating and issued a $230.00 price target on shares of Becton, Dickinson and in a report on Monday, August 14th. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $200.93.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 in the last quarter. Insiders own 1.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/07/becton-dickinson-and-company-bdx-shares-bought-by-hpm-partners-llc.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.